Microbial alternative: Biocatalysts launch pig-free “pancreatic” enzyme
07 Apr 2020 --- Biotech company Biocatalysts has launched an animal-free alternative to pancreatic lipase, a porcine enzyme widely used in a number of food processes. The new enzyme, called Lipomod 888MDP, is a non-genetically modified microbial lipase preparation which is both Kosher and Halal. While the ingredient is not “plant-based” as such, it is made from a fungal preparation, tapping into vegetarian and vegan trends. The development of the microbial alternative comes in the wake of African swine fever (ASF).
Pancreatic lipase is derived from the pancreas of pigs and is commonly used where the hydrolysis of fats is required, from improving the flavor characteristic in enzyme-modified cheeses to releasing the fatty acids from the glycerol backbone of lard or tallow, which in turn generates savory, meaty flavors in pet foods.
Comparative to pancreatic lipase, L888MDP is a microbial lipase enzyme preparation. It is particularly suitable for the hydrolysis of animal fats, breaking down the triglycerides to liberate fatty acids to produce strong flavor characteristics.
L888MDP is active against all three positions on the triglyceride molecule, making it suitable for hydrolysis of complex fats to enhance flavors in both enzyme-modified cheeses and palatants applications.
The new enzyme L888MDP will accommodate consumers who want to distance themselves and their pets from ingredients derived from animals while confronting difficulties in the supply chain, which have disturbed the enzyme's availability.
Pancreatic lipase increasingly hard to find
The development of the microbial alternative came in response to the continued worldwide spread of ASF, a contagious deadly viral disease affecting pigs and wild boars but does not cause disease in humans. Due to the disease, stocks and quality of pancreatic lipase have become increasingly challenging.
ASF is also expected to cause a drop in Asian pork production this year. A March report published by Rabobank outlines a potential growth in local poultry production and international trade if rising supply chain challenges can be managed.
Of course, ASF is not the only disease that is causing global disruptions. Last month, Biocatalysts postponed the official opening of its new state-of-the-art enzyme manufacturing facility until later this year. This step was taken in light of the ongoing development of COVID-19, the company notes, stating that it believes this is the best course of action for the safety and well-being of its staff and visitors.
“The decision was not taken lightly, but with the rapidly changing coronavirus situation, we believe that this is the right decision to take. We are very proud of our new enzyme manufacturing facility and will celebrate its completion at a future date,” says Rod Sears-Black Biocatalysts Managing Director.
To stay up-to-date on how COVID-19 is affecting the food industry, visit FoodIngredientsFirst’s live streaming updates.
Edited by Missy Green
